Hyperuricemia - A Pipeline Analysis Report

Overview of the drug development pipeline for hyperuricemia

It has been observed that hyperuricemia is a condition where the uric acid in the blood level increases. The uric acid passes through the liver and enters the bloodstream. Most of it is excreted through urine or passes through the intestines (to maintain the normal level). The normal uric acid levels are 2.4-6.0 mg/dL in females and 3.4-7.0 mg/dL in males. Purines are also important to regulate the blood uric acid levels. The common symptoms of hyperuricemia include pain while urinating, nausea, increased urge to urinate, joint stiffness, and blood in the urine. A high level of uric acid is a causative factor in gout and urolithiasis. Several public and private companies are focused on the development of drug molecules for the treatment of hyperuricemia. Monotherapy is emerging as the most efficient approach for the treatment of hyperuricemia.

According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for hyperuricemia. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Pipeline analysis report on drug development for hyperuricemia: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of hyperuricemia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.